INTRODUCTION AND OBJECTIVES:
In urothelial carcinoma, genetic alterations in multiple cell-cycle regulations genes are frequent, including key tumor suppressor genes like TP53 and RB1. Prior studies have shown that alterations of TP53 and RB1, analyzed through protein p53 and RB expression respectively have prognostic significance. The goal of this study was to evaluate the correlation between TP53 and RB1 genotypes and phenotypes.
METHODS: Tumor and matched germline DNA were analyzed using the MSK-IMPACT assay that detects alterations in 410 oncogenes and tumor suppressor genes, including TP53 and RB1. A correlation between TP53 and RB1 mutation status and protein expression was performed. Tissue microarrays (TMA) of urothelial carcinoma of the bladder were assessed for p53 and RB expression as a validation cohort.
RESULTS: Overall, 171 patients with a median age of 69.4 years (IQR: 61.7-71.5) were included. Clinical stage was non muscle invasive bladder cancer in 14 (8.2%) patients, muscle invasive bladder cancer in 148 (86.5%) and metastatic in 9 (5.3%). Genetic alterations of TP53 and RB1 were found in 93 (53.8%) and 66 (38.2%) patients respectively. Protein expression was assessed from full section in 65 (38%) patients and from TMA in 106 (62%). Strong and diffuse p53 expression strongly correlated with missense TP53 mutations (n¼43, 78.2%, p<0.0001). In addition, complete lack of p53 expression was seen in tumors harboring truncating TP53 mutations (n¼ 20, 58.8%, p<0.0001). Similarly, loss of RB expression strongly correlated with the presence of RB1 mutations (n¼43, 86%, p<0.0001). Tumors with wildtype TP53 or RB exhibited variable p53 and RB expression. In cases with both invasive and non-invasive components (n¼24), similar patterns of p53 and RB expression were observed.
CONCLUSIONS: The most common pattern of p53 expression that correlated with the presence of TP53 mutations are strong and diffuse nuclear expression (missense mutation) and absence of nuclear expression (truncating mutation). RB1 mutations generally result in loss of RB expression. The concordant pattern of p53 and RB expression between invasive and non-invasive component within the same tumor indicate that alterations in these genes occur early in the development of urothelial carcinoma.
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MP48-18 GERMLINE DNA REPAIR SINGLE NUCLEOTIDE POLYMORPHISMS IN UROTHELIAL CANCER PATIENTS.
INTRODUCTION AND OBJECTIVES:
Single nucleotide polymorphisms (SNPs) in genes involved in carcinogenesis and cancer growth have been investigated for their prognostic value in several cancers, including urothelial (UC). Repair of DNA damage is a key process involved in development of chemotherapy-resistance. The role of germline DNA repair gene (DRG) SNPs in patients with UC has not been explored. We hypothesized that germline SNPs of DRGs could be enriched and potentially associated with outcomes in UC patients exposed to platinum agents.
METHODS: We examined a cohort of 53 UC patients (median age 67, 42 males) enrolled in our IRB-approved Precision Medicine program. Patients had histologically confirmed UC (43 bladder, 10 upper tract UC) and received treatment with platinum-based chemotherapy. We isolated germline DNA from blood lymphocytes or buccal swabs, and used whole exome sequencing (WES) to examine germline SNPs. As a reference for SNP frequencies we used the Exome Aggregation Consortium (ExAC) database, the largest randomly selected germline WES database in general population, also including cancer patients.
RESULTS: Twelve different DRG SNPs were identified in germline DNA samples from 53 patients, affecting genes involved in non-homologous end-joining (RECQL4, n¼18, 54.50%; POLQ, n¼2, 6%), nucleotide excision repair (ERCC6, n¼2, 6%; XPA, n¼1, 3%; CCNH, n¼1, 3%; POLK, n¼1, 3%), homologous recombination (RNF168, n¼1, 3%; RAD17, n¼1, 3%; POLE, n¼1, 3%), Fanconi anemia pathway (POLN, n¼1, 3%), mismatch repair (EXO1, n¼1, 3%) and mitochondrial DNA repair (POLG, n¼2, 6%). The frequency of rs11342077 of the DNA helicase RECQL4 was significantly higher in our cohort (18/53, 34%) compared to its frequency in the ExAC e644 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 
